NCT05189015View on ClinicalTrials.gov

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2023

Conditions
Angiotensin/Renin/Aldosterone HypertensionHypertensionDiabetes Mellitus, Type 2
Interventions
DRUG

Olmesartan

\- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT05189015 - Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension | Biotech Hunter | Biotech Hunter